Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637039 | 0.86 | GRM5 (0.34) | MAPTALDH1A1S1PR2HSP90AA1OPRK1 | |
| SCHEMBL1637054 | 0.83 | ATM (0.47) | MAPTALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL1636983 | 0.82 | ACACB (0.41) | MAPTALDH1A1S1PR2HSP90AA1OPRK1 | |
| SCHEMBL1635696 | 0.78 | ESR1 (0.37) | MAPTALDH1A1S1PR2HSP90AA1OPRK1 | |
| SCHEMBL1636314 | 0.76 | HPGD (0.50) | MAPTALDH1A1HSP90AA1OPRK1CYP1A2 | |
| SCHEMBL28778381 | 0.74 | TTR (0.47) | TTRMAPTALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL738373 | 0.73 | ALDH1A1 (0.44) | MAPTALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL738590 | 0.72 | APP (0.46) | MAPTALDH1A1NPSR1CYP1A2CYP2C9 | |
| SCHEMBL1636350 | 0.71 | TTR (0.40) | TTRMAPTALDH1A1S1PR2HSP90AA1 | |
| SCHEMBL777000 | 0.69 | TTR (0.57) | TTRMAPTALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042506-B1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-7932398-B2 | Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex | UBE INDUSTRIES, LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2042506-A1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | Ube Industries, Ltd. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | CCRL2, CCNL2, ATXN2L | TTR 1002/4885MAPT 4610/4885ALDH1A1 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.